Form 4: Protagonist CEO Sells Shares, Exercises Options

Protagonist Therapeutics CEO Dinesh V. Patel reported exercising stock options and selling common stock, alongside a charitable donation, under a pre-arranged trading plan.

Summary

• Dinesh V. Patel, President and CEO of Protagonist Therapeutics, Inc. (PTGX), reported multiple transactions between January 23 and January 27, 2026.
• On January 23, 2026, Patel made a charitable donation of 6,000 shares of common stock to a donor-advised fund.
• Patel exercised a total of 48,273 stock options across four separate transactions.
• These options included 30,000 shares at an exercise price of $4.21 and 18,273 shares at an exercise price of $21.58.
• Concurrently, Patel sold 48,273 shares of common stock in multiple transactions at weighted average prices ranging from $83.19 to $84.59.
• The transactions were conducted pursuant to a Rule 10b5-1 pre-arranged trading plan.
• Following these transactions, Patel directly beneficially owns 574,505 shares of common stock and 300,000 stock options expiring on October 11, 2026.

Sentiment

Score: 4

Explanation: The sentiment is slightly negative due to significant insider selling, even though it was conducted under a 10b5-1 plan. While the exercise of options indicates value, the subsequent sale of all exercised shares, plus a charitable donation, reduces the CEO's direct common stock holdings, which can be interpreted as a bearish signal by some investors.

Positives

• The exercise of options at significantly lower prices ($4.21 and $21.58) compared to the sale prices ($83.19 to $84.59) indicates a substantial profit for the insider.
• The transactions were executed under a Rule 10b5-1 plan, suggesting they were pre-scheduled and not based on immediate, non-public information.

Negatives

• The CEO sold a significant number of shares (48,273 shares) over a few days, reducing direct beneficial ownership of common stock.
• Insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a lack of confidence or a signal that the stock price may be near a peak.

Future Outlook

NA

Industry Context

This filing reflects routine insider transactions for a biotechnology company executive. Such transactions are common in the industry, especially when executives exercise vested options and sell shares for liquidity or diversification, often under pre-arranged 10b5-1 plans.

Comparison to Industry Standards

• The use of a Rule 10b5-1 plan for these transactions aligns with best practices for corporate insiders to avoid accusations of trading on material non-public information. Many executives at comparable biotech firms like Amgen, Gilead Sciences, or Regeneron Pharmaceuticals utilize similar plans for managing their equity compensation.
• The significant spread between option exercise prices ($4.21, $21.58) and sale prices ($83.19 $84.59) is typical for successful biotech companies where stock appreciation provides substantial returns on executive compensation.

Stakeholder Impact

• Shareholders: May view the insider selling as a negative signal, potentially impacting investor confidence and short-term stock price.
• Employees: No direct impact mentioned, but general market sentiment can affect employee morale and equity value.

Key Dates

Recommendation

While the insider selling is a negative signal, it was conducted under a pre-arranged 10b5-1 plan, which mitigates the immediate concern of trading on new negative information. The significant profit from option exercises also reflects past stock appreciation. Without additional context on the company's fundamentals or future prospects, a "hold" recommendation is appropriate, advising investors to monitor future company performance and broader market trends rather than reacting solely to this insider transaction.

Keywords

Protagonist Therapeutics, PTGX, Dinesh V. Patel, Insider Trading, Form 4, Stock Options, Share Sale, CEO, Biotechnology, Pharmaceuticals, Rule 10b5-1